Abstract:

Objective　To investigate the effect of pentotheobromine combined with edaravone dexcanol in the treatment of elderly patients with acute progressive cerebral infarction. Methods　A total of 82 elderly patients with acute progressive cerebral infarction treated at Hancheng People's Hospital from January 2021 to November 2023 were selected as the study objects, and were divided into a study group and a control group by the random number table method, with 41 cases in each group. There were 23 males and 18 females in the control group; they were (70.98±5.14) years old. There were 25 males and 16 females in the study group; they were (71.74±5.05) years old. The control group took conventional treatment and edaravone dexcanol. The study group took conventional treatment, edaravone dexcanol, and pentoxifylline. Both groups were treated for 2 weeks. The degrees of neurological impairment, clinical efficaceis, cerebral circulation-related indicators, hemorheology, and incidences of adverse reactions were compared between the two groups. t and χ² tests were used. Results　After 2 weeks' treatment, the scores of National Institutes of Health Stroke Scale and modified Rankin Scale in the study group were lower than those in the control group [(4.13±0.64) vs. (5.32±0.75) and (1.02±0.18) vs. (1.19±0.21)], with statistical differences (both P<0.05). The total effective rate of the study group was higher than that of the control group [95.12% (39/41) vs. 80.49% (33/41)], with a statistical difference (P<0.05). After 2 weeks' treatment, the middle cerebral artery peak velocity, average velocity, and cerebral vascular reserve capacity of the study group were higher than those of the control group [(70.03±5.41) cm/s vs. (66.25±5.03) cm/s, (38.24±3.35) cm/s vs. (34.69±3.12) cm/s, and (38.69±3.36)% vs. (35.27±3.15)%], with statistical differences (all P<0.05). After 2 weeks' treatment, the fibrinogen level, hematocyte volume, and plasma viscosity of the study group were lower than those of the control group [(3.19±0.49) g/L vs. (3.75±0.58) g/L, (37.68±2.63)% vs. (40.03±3.04)%, and (1.33±0.21) mPa/s vs. (1.61±0.24) mPa/s], with statistical differences (all P<0.05). There was no difference in the incidence of total adverse reactions between the two groups [12.20% (5/41) vs. 9.76% (4/41); P>0.05]. Conclusion　Pentotheobroline combined with edaravone dexcanol in the treatment of elderly patients with acute progressive cerebral infarction is effective, can improve their neurological function, brain circulation, and blood rheology, and is safe and reliable.

Key words:

The elderly, Acute progressive cerebral infarction, Pentoxifylline, Edaravone dexcanol, Effect

摘要：

目的　探讨己酮可可碱联合依达拉奉右坎醇治疗老年急性进展性脑梗死的效果。方法　前瞻性选取2021年1月至2023年11月韩城市人民医院收治的82例老年急性进展性脑梗死患者为研究对象，采用随机数字表法分为研究组、对照组，各41例。对照组男23例，女18例，年龄（70.98±5.14）岁，给予常规治疗联合依达拉奉右坎醇；研究组男25例，女16例，年龄（71.74±5.05）岁，给予常规治疗、依达拉奉右坎醇联合己酮可可碱。均治疗2周，比较两组神经功能缺损程度、临床疗效、脑循环相关指标、血液流变学及药物不良反应情况。统计学方法采用t检验与χ²检验。结果　治疗2周后，研究组美国国立卫生研究院卒中量表、改良Rankin量表评分均低于对照组［（4.13±0.64）分比（5.32±0.75）分、（1.02±0.18）分比（1.19±0.21）分］，差异均有统计学意义（均P<0.05）；研究组总有效率（95.12%，39/41）高于对照组（80.49%，33/41），差异有统计学意义（P<0.05）；研究组大脑中动脉峰值流速、平均流速、脑血管储备能力高于对照组［（70.03±5.41）cm/s比（66.25±5.03）cm/s、（38.24±3.35）cm/s比（34.69±3.12）cm/s、（38.69±3.36）%比（35.27±3.15）%］，差异均有统计学意义（均P<0.05）；研究组纤维蛋白原、红细胞压积、血浆黏度均低于对照组［（3.19±0.49）g/L比（3.75±0.58）g/L、（37.68±2.63）%比（40.03±3.04）%、（1.33±0.21）mPa/s比（1.61±0.24）mPa/s］，差异均有统计学意义（均P<0.05）；两组总不良反应发生率［12.20%（5/41）比9.76%（4/41）］比较，差异无统计学意义（P>0.05）。结论　己酮可可碱联合依达拉奉右坎醇治疗老年急性进展性脑梗死患者效果显著，可有效改善神经功能、脑循环及血液流变情况，安全可靠。

关键词:

老年, 急性进展性脑梗死, 己酮可可碱, 依达拉奉右坎醇, 疗效